Hans W. Wildiers
Expertise in
10
conditions

Hans W. Wildiers

Leuven, VLG, BE 
Expertise in
10
conditions
Leuven, VLG, BE 

Overview

Hans Wildiers practices practicing medicine in Leuven, Belgium.

Mr. Wildiers is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Brain Stem Cancer, Febrile Neutropenia, and Mastectomy.

He is actively involved in clinical research, co-authoring 370 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Leuven, VLG, Belgium
Other Locations
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Pembrolizumab, Anastrozole
Study Phase: Phase 1
Isolation of Genotype-specific Isoforms of Human Vitamin D-binding Protein (DBP/Gc)
Isolation of Genotype-specific Isoforms of Human Vitamin D-binding Protein (DBP/Gc)
Enrollment Status: Unknown
Publish Date: July 03, 2024
Intervention Type: Other
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC
Enrollment Status: Completed
Publish Date: March 07, 2024
Intervention Type: Drug
Study Drugs: MCLA-128, Trastuzumab, Vinorelbine, Endocrine Therapy
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

369 Total Publications

Determinants of Interest-Holder Perspectives Toward Post-Mortem Tissue Donation in Oncology: A Systematic Review.
Determinants of Interest-Holder Perspectives Toward Post-Mortem Tissue Donation in Oncology: A Systematic Review.
Journal: Psycho-oncology
Published: July 08, 2026

Frequently Asked Questions about Hans W. Wildiers

Is Hans W. Wildiers a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Hans W. Wildiers is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hans W. Wildiers participate in research or clinical trials?

Yes. Hans W. Wildiers has published 369 articles and abstracts on conditions like Breast Cancer. You can view a list of Hans W. Wildiers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wildiers's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile